Current and future medical treatments for menometrorrhagia during the premenopause

Gynecological Endocrinology

Volumn 27, Issue SUPPL. 1, 2011, Pages 1120-1125

  Bouchard, Philippe ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Menometrorrhagia; selective progesterone receptor modulators; treatment; ulipristal acetate

Indexed keywords

11BETA [4 (DIMETHYLAMINO)PHENYL] 4',5' DIHYDRO 6BETA METHYLSPIRO[ESTRA 4,9 DIENE 17BETA,2'(3'H) FURAN] 3 ONE; ASOPRISNIL; CP 8816; DESOGESTREL; ESTROGEN; GESTAGEN; GONADORELIN AGONIST; IRON; LEVONORGESTREL; LONAPRISAN; MEFENAMIC ACID; MIFEPRISTONE; NORETHISTERONE ACETATE; ONAPRISTONE; ORAL CONTRACEPTIVE AGENT; PGL 4001; PLACEBO; TELAPRISTONE; TELAPRISTONE ACETATE; TRANEXAMIC ACID; ULIPRISTAL; UNCLASSIFIED DRUG; WAY 255348;

AMENORRHEA; ANGIOGENESIS; ANOVULATION; ARTERY BLOOD FLOW; BLOOD VESSEL; BONE MASS; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; ENDOCRINE DISEASE; ENDOMETRIUM ABLATION; ENDOMETRIUM POLYP; ESTROGEN RELEASE; EXTRACELLULAR MATRIX; FEMALE; FUTUROLOGY; HEMOSTASIS; HOT FLUSH; HUMAN; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; LEIOMYOMA; LOW DRUG DOSE; MENSTRUAL CYCLE; MENSTRUATION; METRORRHAGIA; OVULATION; PHASE 2 CLINICAL TRIAL (TOPIC); PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TUMOR BLEEDING; TUMOR GROWTH; UTERINE ARTERY; UTERINE ARTERY EMBOLIZATION; UTERUS MYOMA;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL; ENDOMETRIAL NEOPLASMS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEIOMYOMA; LEVONORGESTREL; MENORRHAGIA; METRORRHAGIA; MIFEPRISTONE; NORPREGNADIENES; POLYPS; PREMENOPAUSE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PROGESTERONE; UTERINE NEOPLASMS;

EID: 84055191657     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.638754     Document Type: Review

References (27)

1. Marret H, Fauconnier A, Chabbert-Buffet N, Cravello L, Golfier F, Gondry J, Agostini A, et al.; CNGOF Collège National des Gynécologues et Obstétriciens Français. Clinical practice guidelines on menorrhagia: Management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol 2010;152:133-137.
2. Coulter A, Peto V, Jenkinson C. Quality of life and patient satisfaction following treatment for menorrhagia. Fam Pract 1994;11:394-401.
3. Maybin JA, Critchley HO. Progesterone: A pivotal hormone at menstruation. Ann N Y Acad Sci 2011;1221:88-97.
4. Lockwood CJ. Mechanisms of normal and abnormal endometrial bleeding. Menopause 2011;18:408-411.
5. Shaw RW. Assessment of medical treatments for menorrhagia. Br J Obstet Gynaecol 1994;101 Suppl 11:15-18. (Pubitemid 24227978)
6. Irvine GA, Cameron IT. Medical management of dysfunctional uterine bleeding. Baillieres Best Pract Res Clin Obstet Gynaecol 1999;13:189-202. (Pubitemid 29353805)
7. Roman H, Loisel C, Puscasiu L, Sentilhes L, Marpeau L. [Management of menometrorrhagia in women with and without pregnancy intention: Hierarchy of therapies]. J Gynecol Obstet Biol Reprod (Paris) 2008;37 Suppl 8:S405-S417.
8. De Falco M, Pollio F, Pontillo M, Ambrosino E, Busiello A, Carbone IF, Ciociola F, et al. [GnRH agonists and antagonists in the preoperative therapy of uterine fibroids: Literature review]. Minerva Ginecol 2006;58: 553-560. (Pubitemid 46154884)
9. Rein MS. Advances in uterine leiomyoma research: The progesterone hypothesis. Environ Health Perspect 2000;108 Suppl 5:791-793.
10. Roberts TE, Tsourapas A, Middleton LJ, Champaneria R, Daniels JP, Cooper KG, Bhattacharya S, Barton PM. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: Cost effectiveness analysis. BMJ 2011;342:d2202.
11. Flynn M, Jamison M, Datta S, Myers E. Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol 2006;195:955-964. (Pubitemid 44415640)
12. Mote PA, Balleine RL, McGowan EM, Clarke CL. Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J Clin Endocrinol Metab 1999;84:2963-2971. (Pubitemid 30642036)
13. Li Q, Kannan A, DeMayo FJ, Lydon JP, Cooke PS, Yamagishi H, Srivastava D, et al. The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2. Science 2011;331:912-916.
14. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: Mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293-307. (Pubitemid 40674206)
15. Bouchard P, Chabbert-Buffet N, Fauser BCJM. Selective progesterone receptor modulators in reproductive medicine: Pharmacology, clinical efficacy and safety. Fertil Steril 2011;96:1175-1189.
16. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P; VA2914 Study Group. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: A prospective, randomized, placebocontrolled trial. J Clin Endocrinol Metab 2007;92:3582-3589. (Pubitemid 47435338)
17. Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007;87:1399-1412. (Pubitemid 46829155)
18. Wilkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S, Lawrence AC, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008;93:4664-4671.
19. Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, Blithe DL, Blocker W, Nieman LK. CDB-2914 for uterine leiomyomata treatment: A randomized controlled trial. Obstet Gynecol 2008;111:1129-1136. (Pubitemid 351620347)
20. Nieman LK, Blocker W, Nansel T, Mahoney S, Reynolds J, Blithe D, Wesley R, Armstrong A. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: A randomized, double-blind, placebocontrolled, phase IIb study. Fertil Steril 2011;95:767-72.e1.
21. Xu Q, Takekida S, Ohara N, Chen W, Sitruk-Ware R, Johansson ED, Maruo T. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5'-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 2005;90:953-961. (Pubitemid 40279221)
22. Xu Q, Ohara N, Chen W, Liu J, Sasaki H, Morikawa A, Sitruk-Ware R, et al. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 2006;21:2408-2416. (Pubitemid 44530620)
23. Ravet S, Munaut C, Blacher S, Brichant G, Labied S, Beliard A, Chabbert-Buffet N, et al. Persistence of an intact endometrial matrix and vessels structure in women exposed to VA-2914, a selective progesterone receptor modulator. J Clin Endocrinol Metab 2008;93: 4525-4531. (Pubitemid 352789556)
24. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelvemonth safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005;12:227-233. (Pubitemid 40800387)
25. Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: Changes and consequences. Hum Reprod Update 2007;13:567-580. (Pubitemid 350018525)
26. Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, Williams AR, Blithe DL. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008;21:591-598. (Pubitemid 351589653)
27. Lakha F, Ho PC, Van der Spuy ZM, Dada K, Elton R, Glasier AF, Critchley HO, et al. A novel estrogen-free oral contraceptive pill for women: Multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod 2007;22:2428-2436. (Pubitemid 47289057)